Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents
Status:
Withdrawn
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate safety, tolerability, pharmacokinetics
(PK) and preliminary efficacy of idelalisib; and to establish recommended phase 2 doses
(RP2D) of idelalisib in combination with rituximab, ifosfamide, carboplatin, etoposide (RICE)
in children and adolescents with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
or mediastinal B-cell lymphoma (MBCL)